Federico Oppenheimer

List of Publications by Year
in descending order

123 papers	3,787 citations	109321 35 h-index	144013 57 g-index
129 all docs	129 docs citations	129 times ranked	4703 citing authors

#	Article	IF	Citations
1	The Case | Persistent fever in a hemodialysis patient. Kidney International, 2022, 101, 193-194.	5.2	1
2	Outcomes after 20Âyears of experience in minimally invasive living-donor nephrectomy. World Journal of Urology, 2022, 40, 807-813.	2.2	6
3	Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation, 2022, 106, 1430-1439.	1.0	18
4	FC 107: Development and Validation of a Machine Learning-Based Virtual Biopsy System in Kidney Transplant Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
5	MO957: Breakthrough Infections Following Mrna Sars-Cov-2 Vaccination in Kidney Transplant Recipients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
6	FC002: Humoral and Cellular Immune Responses After a Three-Dose Course of Mrna-1273 Covid-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	FC 110: Survival Benefit of Preemptive Simultaneous Pancreas-Kidney Transplantation. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	The impact of functional delayed graft function in the modern era of kidney transplantation â€“ A retrospective study. Transplant International, 2021, 34, 175-184.	1.6	9
9	Taking care of kidney transplant recipients during the COVIDâ€19 pandemic: Experience from a medicalized hotel. Clinical Transplantation, 2021, 35, e14132.	1.6	5
10	COVID-19 in transplant recipients: The Spanish experience. American Journal of Transplantation, 2021, 21, 1825-1837.	4.7	156
11	Modeling patients as decision making units: evaluating the efficiency of kidney transplantation through data envelopment analysis. Health Care Management Science, 2021, 24, 55-71.	2.6	5
12	Outcomes From Brain Death Donors With Previous Cardiac Arrest Accepted for Pancreas Transplantation. Annals of Surgery, 2021, 273, e230-e238.	4.2	7
13	A hybrid data envelopment analysisâ€"artificial neural network prediction model for COVID-19 severity in transplant recipients. Artificial Intelligence Review, 2021, 54, 4653-4684.	15.7	9
14	SARS-CoV-2 Infection After Full Vaccination in Kidney Transplant Recipients. Transplantation, 2021, 105, e278-e279.	1.0	5
15	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open, 2021, 11, e052138.	1.9	24
16	Influence of Persistent Inflammation in Follow-Up Biopsies After Antibody-Mediated Rejection in Kidney Transplantation. Frontiers in Medicine, 2021, 8, 761919.	2.6	4
17	B Cell-Derived Extracellular Vesicles Reveal Residual B Cell Activity in Kidney Graft Recipients Undergoing Pre-Transplant Desensitization. Frontiers in Medicine, 2021, 8, 781239.	2.6	4
18	Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. American Journal of Transplantation, 2020, 20, 3030-3041.	4.7	78

#	Article	IF	Citations
19	P1699EFFECT OF UREMIA IN THE POSTOPERATIVE OF PREEMPTIVE LIVING-DONOR KIDNEY TRANSPLANT PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
20	Psychosocial risk factors for impaired health-related quality of life in living kidney donors: results from the ELIPSY prospective study. Scientific Reports, 2020, 10, 21343.	3.3	8
21	Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. American Journal of Transplantation, 2020, 20, 2958-2959.	4.7	65
22	Successful use of nonantigenâ€specific immunoadsorption with antihuman Igâ€columns in kidney graft antibodyâ€mediated rejection. Journal of Clinical Apheresis, 2020, 35, 188-199.	1.3	5
23	Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection. Frontiers in Cell and Developmental Biology, 2020, 8, 10.	3.7	21
24	The development of a predictive model of graft function in uncontrolled donors after circulatory death: validity of a pulsatile renal preservation machine cut-off value for kidney acceptance. Nephrology Dialysis Transplantation, 2019, 34, 531-538.	0.7	7
25	Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche. Scientific Reports, 2019, 9, 11177.	3.3	11
26	Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation. BMC Nephrology, 2019, 20, 274.	1.8	6
27	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplantation Reviews, 2019, 33, 191-199.	2.9	12
28	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
29	Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program. Transplantation Proceedings, 2019, 51, 3222-3226.	0.6	3
30	Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies. Transplant International, 2018, 31, 938-939.	1.6	2
31	Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection. Transplantation, 2018, 102, 1075-1084.	1.0	15
32	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. Journal of the American Society of Nephrology: JASN, 2018, 29, 620-635.	6.1	94
33	Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor. Transplantation, 2018, 102, S363.	1.0	1
34	Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice. Transplantation, 2018, 102, S191.	1.0	0
35	Pancreas Graft Outcomes in Living versus Deceased Kidney Donor in Pancreas after Kidney Transplant Recipients. Transplantation, 2018, 102, S449.	1.0	0
36	Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrology, 2018, 19, 261.	1.8	31

#	Article	IF	Citations
37	Outcomes from Brain Death Donors with Cardiac Arrest Accepted for Pancreas Transplantation. Transplantation, 2018, 102, S450.	1.0	0
38	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
39	Assessment of donor satisfaction as an essential part of living donor kidney transplantation: an eleven-year retrospective study. Transplant International, 2018, 31, 1332-1344.	1.6	16
40	Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients. Nephrology Dialysis Transplantation, 2018, 33, 2052-2059.	0.7	9
41	Histopathological evaluation of pretransplant donor biopsies in expanded criteria donors with high kidney donor profile index: a retrospective observational cohort study. Transplant International, 2017, 30, 975-986.	1.6	22
42	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3â€year retrospective cohort study. Transplant Infectious Disease, 2017, 19, e12724.	1.7	3
43	Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades. Nefrologia, 2017, 37, 253-266.	0.4	12
44	Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. Nefrologia, 2017, 37, 253-266.	0.4	7
45	Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. Transplant International, 2016, 29, 1008-1016.	1.6	11
46	An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI. Transplant International, 2016, 29, 362-368.	1.6	9
47	Borderline rejection in <scp>ABO</scp>â€incompatible kidney transplantation. Clinical Transplantation, 2016, 30, 872-879.	1.6	7
48	Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. Transplant International, 2016, 29, 1317-1328.	1.6	16
49	mTOR Inhibition. Transplantation Direct, 2016, 2, e65.	1.6	10
50	Chronic renal patient across the continuum of the healthcare from family practitioner to nephrologists. International Journal of Integrated Care, 2016, 16, 228.	0.2	0
51	Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation, 2015, 99, 1709-1714.	1.0	69
52	Identifying endpoints to predict the influence of immunosuppression on longâ€term kidney graft survival. Clinical Transplantation, 2015, 29, 644-653.	1.6	8
53	A case of esophageal adenocarcinoma on long-term rapamycin monotherapy. Transplant International, 2015, 28, 1240-1244.	1.6	3
54	FP899DEGREE OF LIVER INVOLVEMENT IN STABLE KIDNEY TRANSPLANT PATIENTS WITH HEPATITIS C INFECTION: A SINGLE-CENTER EXPERIENCE. Nephrology Dialysis Transplantation, 2015, 30, iii376-iii376.	0.7	0

#	Article	IF	Citations
55	Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation. Endocrine, 2015, 49, 267-273.	2.3	5
56	Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Nephrology Dialysis Transplantation, 2015, 30, 475-480.	0.7	47
57	Cystinosis in adult and adolescent patients: Recommendations for the comprehensive care of cystinosis. Nefrologia, 2015, 35, 304-321.	0.4	21
58	Polyclonal Versus Monoclonal Induction Therapy in a Calcineurin Inhibitorâ€“Free Immunosuppressive Therapy in Renal Transplantation: A Comparison of Efficacy and Costs. Transplantation Proceedings, 2015, 47, 45-49.	0.6	7
59	Set point of calcium in severe secondary hyperparathyroidism is altered and does not change after successful kidney transplantation. Endocrine, 2015, 48, 709-711.	2.3	5
60	Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers. Transplantation Proceedings, 2015, 47, 2340-2343.	0.6	6
61	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access Journal of Clinical Trials, 2014, , 45.	1.5	19
62	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney International, 2014, 85, 1434-1443.	5.2	38
63	Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre. BioMed Research International, 2014, 2014, 1-7.	1.9	19
64	Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation. Transplantation Research, 2014, 3, 4.	1.5	7
65	Primary brain lymphomas after kidney transplantation: an under-recognized problem?. Journal of Nephrology, 2014, 27, 95-102.	2.0	12
66	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplantation Reviews, 2014, 28, 84-91.	2.9	65
67	Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transplant International, 2013, 26, 177-186.	1.6	32
68	Longâ€term outcome of antineutrophil cytoplasmic antibodyâ€associated small vessel vasculitis after renal transplantation. Clinical Transplantation, 2013, 27, 338-347.	1.6	37
69	Kidneys From Donors With Incidental Renal Tumors. Transplantation, 2013, 95, 1129-1133.	1.0	25
70	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. Transplantation, 2013, 96, 480-486.	1.0	8
71	Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation. Therapeutic Drug Monitoring, 2012, 34, 143-147.	2.0	23
72	Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrology Dialysis Transplantation, 2012, 27, iv39-iv46.	0.7	85

#	Article	IF	Citations
73	Role of Oncogenic Pathways and KRAS/BRAF Mutations in the Behavior of Colon Adenocarcinoma in Renal Transplant Patients. Transplantation, 2012, 93, 509-517.	1.0	7
74	Renal Dysfunction in the Setting of HIV/AIDS. Current HIV/AIDS Reports, 2012, 9, 187-199.	3.1	22
75	New concepts and best practices for management of pre- and post-transplantation cancer. Transplantation Reviews, 2012, 26, 261-279.	2.9	82
76	mTOR inhibitorâ€“associated proteinuria in kidney transplant recipients. Transplantation Reviews, 2012, 26, 27-29.	2.9	65
77	Renal transplantation in HIV-infected patients: 2010 update. Kidney International, 2011, 79, 825-842.	5.2	65
78	Preemptive Use of Mammalian Target of Rapamycin Inhibitors in Living Donor Transplantation. Transplantation Proceedings, 2011, 43, 2568-2573.	0.6	1
79	Are HIV-Infected Donors Suitable for Renal Transplantation?. Transplantation, 2011, 91, e22-e23.	1.0	5
80	Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. Transplant International, 2011, 24, e6-e12.	1.6	62
81	Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplantation Reviews, 2011, 25, 91-101.	2.9	95
82	Reply to Ramya Nagarajan, Shanmugasundaram Rajaian, Nitin S. Kekre's Letter to the Editor re: Mireia Musquera, Lluis L. Peri, Ricardo Alvarez-Vijande, et al. Orthotopic Kidney Transplantation: An Alternative Surgical Technique in Selected Patients. Eur Urol 2010;58:927â€“33. European Urology, 2011, 59, e28.	1.9	0
83	Feasibility of Transvaginal Natural Orifice Transluminal Endoscopic Surgeryâ€“Assisted Living Donor Nephrectomy: Is Kidney Vaginal Delivery the Approach of the Future?. European Urology, 2011, 59, 1019-1025.	1.9	81
84	Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrology Dialysis Transplantation, 2011, 26, 3784-3793.	0.7	37
85	Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?. CKJ: Clinical Kidney Journal, 2011, 4, 256-257.	2.9	2
86	Efficacy of Eculizumab in the Treatment of Recurrent Atypical Hemolytic-Uremic Syndrome After Renal Transplantation. Transplantation, 2010, 89, 903-904.	1.0	75
87	Distinct Immunohistochemical Phenotype of Nonmelanoma Skin Cancers Between Renal Transplant and Immunocompetent Populations. Transplantation, 2010, 90, 986-992.	1.0	20
88	Orthotopic Kidney Transplantation: An Alternative Surgical Technique in Selected Patients. European Urology, 2010, 58, 927-933.	1.9	49
89	Characterization of Î³Î´ T cell subsets in organ transplantation. Transplant International, 2010, 23, 1045-1055.	1.6	68
90	Renal transplantation in patients with hepatitis C virus antibody. A long national experience. CKJ: Clinical Kidney Journal, 2010, 3, ii41-ii46.	2.9	18

#	Article	IF	Citations
91	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation, 2009, 24, 2269-2276.	0.7	81
92	PULSATILE PERFUSION IMPROVES KIDNEY PRESERVATION AND PROVIDES INFORMATION ABOUT ORGAN VIABILITY IN ORGANS FROM EXPANDED CRITERIA DONORS. Journal of Urology, 2009, 181, 805-806.	0.4	0
93	Health-Related Quality of Life of Patients Receiving Low-toxicity Immunosuppressive Regimens: A Substudy of the Symphony Study. Transplantation, 2009, 87, 1210-1213.	1.0	9
94	KIDNEY TRANSPLANT FROM DONORS AFTER UNEXPECTED CARDIAC DEATH (DCD). Journal of Urology, 2008, 179, 662-663.	0.4	0
95	KIDNEY OUTCOME IN THE CONTEXT OF COMBINED LIVER- KIDNEY TRANSPLANTATION. Journal of Urology, 2008, 179, 695-696.	0.4	2
96	Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney International, 2008, 74, S94-S99.	5.2	46
97	Sympathetic Dystrophy Associated With Sirolimus Therapy. Transplantation, 2008, 85, 290-292.	1.0	26
98	Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplanted Patients With Secondary Hyperparathyroidism. Transplantation, 2008, 86, 413-417.	1.0	87
99	Fluvastatin in the Prevention of Renal Transplant Vasculopathy: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Transplantation, 2008, 86, 82-87.	1.0	24
100	Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrology Dialysis Transplantation, 2007, 22, 2316-2321.	0.7	32
101	The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections. Transplantation, 2007, 83, 1493-1500.	1.0	77
102	Impact of Long-Term Therapy With FTY720 or Mycophenolate Mofetil on Cardiac Conduction and Rhythm in Stable Adult Renal Transplant Patients. Transplantation, 2007, 83, 645-648.	1.0	11
103	Sequential Quadruple Immunosuppression Including Sirolimus in Extended Criteria and Nonheartbeating Donor Kidney Transplantation. Transplantation, 2007, 84, 429-432.	1.0	15
104	Weekly risedronate in kidney transplant patients with osteopenia. Transplant International, 2007, 20, 708-711.	1.6	35
105	Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transplant International, 2007, 21, 071115125226003-???.	1.6	27
106	Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. Clinical Transplantation, 2007, 21, 441-448.	1.6	6
107	Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant. Transplantation, 2006, 81, 202-206.	1.0	91
108	Follow-up after renal transplantation with organs from donors after cardiac death. Transplant International, 2006, 19, 715-719.	1.6	45

#	Article	IF	Citations
109	Treatment of humoral rejection in kidney transplantation. Transplantation Reviews, 2006, 20, 95-103.	2.9	4
110	Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrology Dialysis Transplantation, 2006, 21, 488-493.	0.7	82
111	1690: Orthotopic Renal Transplant: An Alternative Surgical Technique in Selected Cases. Journal of Urology, 2006, 175, 544-544.	0.4	0
112	Sirolimus Monotherapy: Feasible Immunosuppression for Long-Term Follow-up of Kidney Transplantation???A Pilot Experience. Transplantation, 2005, 80, 1344-1348.	1.0	12
113	The impact of donor age on the results of renal transplantation. Nephrology Dialysis Transplantation, 2004, 19, iii11-iii15.	0.7	70
114	Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. American Journal of Transplantation, 2004, 4, 1869-1875.	4.7	229
115	Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. Journal of Bone and Mineral Metabolism, 2004, 22, 254-259.	2.7	32
116	Renoprotective Effects of Losartan in Renal Transplant Recipients. Nephron Clinical Practice, 2003, 95, c84-c90.	2.3	27
117	Percutaneous renal artery embolisation of non-functioning renal allografts with clinical intolerance. Transplant International, 2002, 15, 149-155.	1.6	23
118	Role of transforming growth factorâ€Î²1 in the progression of chronic allograft nephropathy. Nephrology Dialysis Transplantation, 2001, 16, 114-116.	0.7	78
119	Effects of Losartan and Amlodipine on Intrarenal Hemodynamics and TGF-Î²1 Plasma Levels in a Crossover Trial in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2001, 12, 822-827.	6.1	96
120	Indium-111 labelled platelet scintigraphy can predict the immunological origin of fever in patients on dialysis carrying a non-functioning renal allograft. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 314-318.	6.4	2
121	Losartan decreases plasma levels of TGF-Î²1 in transplant patients with chronic allograft nephropathy. Kidney International, 1999, 56, 714-719.	5.2	142
122	Ulnar nerve compressionâ€”a case of giant uremic tumoral calcinosis. Acta Orthopaedica, 1997, 68, 302-304.	1.4	13
123	Simultaneous Aortic Bifurcation Graft and Kidney Transplantation from the same Multi-Organ Donor: A New Therapeutic Tool in Complex Renal Transplantation. Journal of Urology, 1996, 156, 2000-2001.	0.4	2